🇺🇸 FDA
Patent

US 11746109

Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate

granted A61KA61K9/485A61K9/4858

Quick answer

US patent 11746109 (Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate) held by Takeda Pharmaceutical Company Limited expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K9/485, A61K9/4858, A61P, A61P35/00